The long median survival time of patients with follicular non-Hodgkin's lymphoma (NHL), means that the efficacy of new treatments are difficult to assess in the short term. Bcl-2 is an inhibitor of apoptosis and overexpression of the bcl-2 gene in the blood or bone marrow is a feature in up to 85% of patients with follicular NHL. Levels of bcl-2 + cells in the peripheral blood or bone marrow therefore are a useful measure of disease status in such patients and can be detected by polymerase chain reaction (PCR). Complete bcl-2 clearance from the bone marrow (molecular remission) following autologous stem cell transplant (ASCT) for follicular NHL is considered to be an important prognostic factor for disease-free survival. Tumour cell contamination of the stem cell grafts used in ASCT is commonly associated with relapse. This can be addressed by purging the stem cell harvest prior to transplantation. Various methods of in vitro purging after stem cell collection have been shown to reduce the level of contamination but yield is invariably reduced and grafts remain bcl-2 positive. However, in vivo purging with rituximab during the process of collection has been used to obtain bcl-2-negative stem cell harvests without compromising the yield. Rituximab is a monoclonal antibody licensed for treatment of relapsed and refractory low-grade or follicular NHL. Rituximab targets the CD20 antigen, which is found on cells of the B cell lineage. When used for in vivo purging it depletes the peripheral blood of CD20-positive cells and prevents contamination by lymphoma cells. Molecular remission, as measured by bonemarrow bcl-2 clearance, has been achieved in 7/7 patients with follicular NHL at 1 year after treatment with ASCT using rituximab as an 'in vivo purse', followed by rituximab maintenance. Early clinical outcomes are also encouraging.
Indolent or low-grade non-Hodgkin's lymphoma (NHL), of which follicular NHL is the most common variant, has a median survival of 7-10 years. Chemotherapy treatments can induce clinical responses in follicular NHL, but the disease follows a continually remitting and relapsing pattern, with progressively shorter duration of remission with each successive treatment. Patients treated with chemotherapy on diagnosis do not show any survival advantage compared with those treated only when symptoms require palliation. 1 Anthracycline-containing regimens increase response rates in follicular lymphoma, when compared to other chemotherapies such as chlorambucil. 2, 3 However, no chemotherapy regimen has demonstrated any impact on overall survival and no curative treatments are currently available for follicular NHL. Novel therapies to improve outcomes in follicular NHL have been the subject of investigation for some time.
Owing to the relatively long median survival of patients with this disease, clinical studies require very long followup to show any effect on survival. In order to assess the efficacy of new treatments at an early stage, endpoints other than survival are necessary. A promising, although as yet unproved, such 'surrogate' endpoint is the clearance of cells containing overexpression of the bcl-2 gene from the blood and bone marrow of patients. This article reviews the use of bcl-2 status as a surrogate endpoint in follicular NHL, particularly in the autologous stem cell transplantation (ASCT) setting, and the use of rituximab, the human/mouse chimeric monoclonal antibody, to clear bcl-2-positive cells from stem cell harvests and from bone marrow or peripheral blood of patients following ASCT.
The bcl-2 gene rearrangement in follicular NHL
The characteristic t(14:18) gene translocation leads to overexpression of the bcl-2 gene in the bone marrow of around 85% of patients with follicular NHL, 4 and cells bearing this translocation can be detected in the peripheral blood or bone marrow by the highly sensitive polymerase chain reaction (PCR) technique. 4, 5 In the t(14:18) translocation, the bcl-2 gene is moved from chromosome 18 to the immunoglobulin heavy chain (IgH) locus on chromosome 14 ( Figure 1 ). 6 The bcl-2 gene product is an inhibitor of apoptosis, and it is believed that bcl-2 overexpression caused by the translocation may be an important factor in lymphomagenesis. 7 PCR for t(14:18) translocation provides a sensitive and convenient measure of minimal residual disease; patients may frequently still have PCR-detectable bcl-2-positive cells in the bone marrow even when in clinical complete remission. 4 Clearance of these bcl-2-positive cells from the bone marrow is referred to as 'molecular remission'.
Induction of molecular remission in patients receiving ASCT
Molecular remission may be achieved following autologous stem cell transplantation (ASCT) for follicular NHL, and there is a clear association between the induction of molecular remission and progression-free survival. 8 In fact, Gribben et al 4 and Freedman et al 8 have observed that molecular remission in the bone marrow following transplantation is the most important prognostic factor for diseasefree survival in patients undergoing autologous stem ASCT for follicular lymphoma. Outside the transplantation setting, an association between bcl-2 status and clinical outcome has not been definitively established, since conventional chemotherapies do not frequently induce molecular remission. 4 However, available evidence does support the likelihood of some correlation. Lopez-Guillermo et al 9, 10 have observed increased failure-free survival in those patients that achieved molecular remission following chemotherapy. Following rituximab monotherapy, longer time to progression has been reported in patients who became bcl-2 negative in the bone marrow, compared with those who did not. 11, 12 Peripheral blood can also be monitored for bcl-2 status. Although PCR negativity in the blood is not as strong a prognostic factor for clinical outcome as it is in the bone marrow 13 removal of bcl-2-positive cells from the peripheral blood may indicate at least partial elimination of minimal residual disease.
Contamination of bone marrow stem cell grafts with bcl-2-positive cells has also been shown to predict for relapse after autologous bone marrow transplantation. 8, 14 Several methods of purging stem cell harvests of malignant cells in vitro have been developed, using monoclonal antibodies, drugs and cytotoxic agents. [14] [15] [16] These methods have met with variable success, however, often resulting in only partial depletion of tumour cells with PCR-detectable bcl-2-positive cells remaining in the graft and in the bone marrow of the patient post transplant. Freedman et al were only able to successfully purge 42% of bone marrow grafts after ex vivo treatment with three monoclonal antibodies. 14 
Bone Marrow Transplantation
Improved strategies to purge stem cell and bone marrow grafts and to prevent relapse in patients receiving ASCT are therefore required.
In vivo purging with rituximab to obtain bcl-2 free stem cell harvests and molecular remissions in patients undergoing ASCT Rituximab is licensed for the treatment of relapsed and refractory low-grade and follicular NHL, and is under development for patients with aggressive NHL, for previously untreated indolent NHL patients, and for patients with other B cell malignancies. 17 The target antigen for rituximab is CD20, which is expressed on all cells of the B cell lineage but not on stem cells, and in 90% of NHL. 18 Rituximab consists of a murine antigen binding region and a human Fc region. The human component of rituximab interacts with host effector mechanisms to kill CD20-positive cells by a variety of mechanisms, including complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. 19 Rituximab can also exert direct effects on tumour cells via the induction of apoptosis. 20 The mechanisms of action of rituximab are different to conventional chemotherapy, providing a strong rationale for combining the two treatments in combination immunochemotherapy. Encouragingly, combinations such as rituximab plus CHOP (cyclophosphamide, hydroxydaunomycin, oncovin and prednisone) have not only yielded very high clinical response rates (75-95%), but are also able to induce molecular remissions in most patients. 21, 22 The use of rituximab for in vivo purging in ASCT is currently under investigation. In contrast to in vitro purging methods, which are designed to remove contaminating tumour cells after the stem cell harvest, the administration of rituximab in vivo depletes the peripheral blood of all CD20 + cells, 23 preventing contamination of the graft by lymphoma cells. In vivo purging with rituximab has been used by several investigators to obtain bcl-2-negative stem cell harvests, without compromising the yield or function of stem cells. [24] [25] [26] Further to these encouraging data, a phase I/II trial of in vivo purging with rituximab in 18 patients with follicular lymphoma undergoing ASCT has been undertaken. In this study, in addition to evaluation of clinical endpoints, bcl-2 status was monitored throughout treatment and follow-up. Patients were given a single purging dose of rituximab before stem cell collection with two further cycles (375 mg/m 2 , four once-weekly infusions) given 8 and 24 weeks post transplant to consolidate remission and prevent regrowth of residual tumour cells in the patient.
All 18 patients treated with rituximab in vivo purging and consolidated immunotherapy have achieved a response (17 patients with a complete response or unconfirmed complete response), and only one has subsequently relapsed, after a short median follow-up of 1 year.
Early clinical outcomes from this study are encouraging, and long-term follow-up data on disease-free and overall survival are awaited with interest. Molecular monitoring of bcl-2 status, however, can be highly informative in the short term. Figure 2 shows bcl-2 status of 12 patients during treatment and follow-up. All patients were bcl-2 positive on diagnosis with eight patients showing histologically positive lymphoma cells in the bone marrow. Following in vivo purging and transplantation, seven of 10 assessable patients were bcl-2 negative in the bone marrow and/or peripheral blood, with a further two patients who showed a weak positive signal converting to bcl-2-negative status after the first cycle of rituximab maintenance therapy. The remaining patient was bcl-2 negative in the blood, but remained positive in the bone marrow. Seven out of seven evaluable patients remained PCR negative in bone marrow and peripheral blood 1 year after treatment.
One interesting finding was that stem cell harvests remained largely bcl-2 positive following the single purging administration of rituximab. The most likely explanation is that non-viable malignant cells, which had been killed by rituximab but not yet cleared from the circulation, were the source of the contamination. Certainly, contamination was not evident following reinfusion, as the majority of patients (7/10) were bcl-2 negative post transplant, even prior to the commencement of rituximab maintenance therapy.
Conclusions
The t(14:18) translocation of the bcl-2 gene may be a useful surrogate endpoint to monitor treatment efficacy in indolent NHL. Due to the long median survival in indolent disease, effects of new treatments on disease-free and overall survival may take a long time to become evident.
Evaluation of bcl-2 status allows early analysis of such treatments.
The data presented herein show that in vivo purging and consolidated immunotherapy with rituximab can produce molecular remissions in the bone marrow and peripheral blood of patients following transplant. The treatment was well tolerated and did not affect stem cell yield or function. Others have also shown that in vivo purging with rituximab has been shown to produce bcl-2-negative stem cell grafts without adverse effects on stem cell yield or function. 25, 26 In the transplantation setting, there is a clear correlation between molecular remission and disease-free survival; 8 bcl-2-negative status in the bone marrow is therefore a highly desirable goal of treatment.
The ability to achieve long-term molecular remission on a consistent basis with rituximab in vivo purging and maintenance suggests this regimen may lead to improved clinical outcomes for patients undergoing ASCT for treatment of follicular NHL.
